Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 11/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18291201 | 0.83 | UHRF1 (0.36) | OPRL1OPRM1MAP4K1PIM1ALDH1A1 | |
| SCHEMBL18291470 | 0.82 | NOS3 (0.40) | MAP4K1PIM1FLT3SOS1SLC6A2 | |
| SCHEMBL20249425 | 0.77 | PIM1 (0.39) | MAP4K1PIM1SOS1SLC6A2SLC6A4 | |
| SCHEMBL20249449 | 0.76 | SOS1 (0.34) | MAP4K1PIM1ALDH1A1SOS1SLC6A2 | |
| SCHEMBL8307179 | 0.75 | HSD17B10 (0.44) | ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL2366300 | 0.73 | HTR1A (0.45) | ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20249104 | 0.71 | SLC6A2 (0.38) | OPRL1OPRM1MAP4K1PIM1SLC6A2 | |
| SCHEMBL3661183 | 0.71 | P2RX7 (0.45) | SOS1SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL5913607 | 0.70 | P2RX7 (0.44) | SOS1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20037593 | 0.69 | PIM1 (0.35) | MAP4K1PIM1ALDH1A1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | OPRL1 4655/4885OPRM1 4815/4885MAP4K1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.